Conceivable Life Sciences Raises $50 Million For AI Automation And Robotic Precision in IVF

Conceivable Life Sciences, the World’s First AI-Powered Automated IVF Lab, led by Joshua Abram, Alan Murray, Alejandro Chavez-Badiola, Jacques Cohen, Stephanie Kuku, Ann Watson, and others, has secured $50 million in Series A led by numerous prominent investors, including ARTIS Ventures, Stride, and ACME Ventures.

The IVF process is costly, stressful, and inconsistent, with U.S. cycles averaging $12,000–$25,000 and many families needing multiple rounds. Reliance on manual expertise and strict health regimens adds to the burden, making consistency and improved outcomes a critical need.

Conceivable’s lab platform, Aura, integrates AI algorithms with robotic hardware to automate the full IVF workflow, from dish and sperm preparation to egg retrieval, fertilization, and incubation, enabling greater precision and consistency.

Conceivable’s platform has already been used in a pilot study that resulted in 18 healthy births. A larger trial with nearly 120 participants is underway and expected to conclude by year’s end, paving the way for a commercial launch early next year. The new funding will support this rollout and advance its mission of empowering families through more consistent, successful fertility outcomes.

Dr. Alejandro Chavez-Badiola, reproductive endocrinologist and co-founder, aims to bring consistent outcomes and advanced technology to fertility care, reducing the uncertainty inherent in a largely manual IVF process. While the AI-driven IVF space is competitive, with players like Nova IVF and SpOvum Technologies innovating in embryo assessment and injection techniques, Conceivable differentiates itself by addressing the full workflow rather than offering point solutions. The global fertility market is booming, projected to reach nearly $87 billion by 2034, with growing employer adoption of fertility benefits, positioning comprehensive solutions like Conceivable for significant impact.